ELP3 and breast cancer: Our results showed that the circulating level of hsa_circ_0001785 (Circ‐ELP3) in breast cancer patients before treatment was upregulated compared with controls (p‐value = 0.0106), while after treatment, the level of this circRNA was significantly decreased compared to pre‐treatment status (p‐value = 0.01) and, moreover, this value had no statistically significant difference with control group (p‐value = 0.9451) (Figure 1A).